Lippia sidoides Cham. (Verbenaceae), popularly known as alecrim-pimenta, is an aromatic plant typical of the Brazilian northeast, whose leaves are used to extract essential oil from with antimicrobial and antioxidant activity. Thymol, a major component of the oil, is one of the most potent natural antiseptics, however some essential oils can cause irritation when applied directly to the skin. The study and development of formulations aims to optimize the pharmacological action of the active and when possible minimize the undesired effects, and in this sense, nanotechnology is a very useful tool. Thus, the present study was aimed at the development and characterization of nanosystems (nanocapsules and nanoemulsions) containing essential oil extracted from Lippia sidoides (Alecrim Pimenta) standardized on terpene bioactive thymol. The preparation of the nanosystems was performed by the nanoprecipitation method. Eight formulations were made, 5 formulations of nanocapsules (A, B, C, D and E), and 3 nanoemulsions (F, G and H). The preparations were characterized by diameter, polydispersity index (PDI), potential zeta - PZ (electrophoretic mobility), active content (high performance liquid chromatography - HPLC), active release (Franz cells) and neutrophil degranulation was evaluated by the release of the enzyme myeloperoxidase (MPO). Almost all formulations demonstrated homogeneous macroscopic appearance, with the exception of nanocapsules A and B; and of the nanoemulsion H, which presented precipitation soon after the production. Macroscopically stable formulations were evaluated for size with particles between 174 to 388 nm and PZ with negative values between -12 and -22 mV. In relation to the PDI, formulations that presented values lower than 0.2 were only formulations E (nanocapsules) and F (nanoemulsion), these being those selected for subsequent studies. The assay assay revealed a process yield of greater than 70%, where the nanoemulsion F had a content of 2.9 mg / mL thymol and the 2.8 mg / mL E nanocapsule formulation. The active release test from the nanocapsules E showed that in the first 6 hours 14.4% of the active had already been released, after 12 hours, 27.8%, in 24 hours 38.9%, and in 48 hours approximately of thymol was already available in the medium. The PMA-induced degranulation assay demonstrated that after 30 minutes of incubation, the 100 ng / mL E nanocapsules reduced the release of MPO by up to 52%. Indomethacin (36 μg / mL), the standard drug, inhibited neutrophil degranulation in 76% (76, 32 ± 1.06%). Therefore, with the results obtained in this research, it was possible to conclude that the preparation process of the nanosystems presented a narrow distribution of particle size, high yield, and the dosing method allowed to standardize nanocapsules and nanoemulsions as to the content of the bioactive compound thymol. It was also verified that the formulation E demonstrated to sustain the release of the active for at least 48 hours, which indicates that this nanotechnological input has great potential for the development of cosmetic products in which it is expected a long lasting effect. In addition, the in vitro assay of the effects of the nanocapsules E on the degranulation of the neutrophils activated by PMA demonstrated that this nanosystem was able to inhibit in a manner comparable to the standard the release of the enzyme myeloperoxidase, thus suggesting potential anti-inflammatory and antioxidant activity.